Should Gemtuzumab Ozogamicin Be Re-added to the Therapeutic Armamentarium for Acute Myeloid Leukemia?

Sept. 17, 2012

Although gemtuzumab ozogamicin has been withdrawn from the marketplace, three randomized trials prompt review of that decision.